【摘要】 目的观察多西他赛联合卡铂一线治疗老年晚期表皮生长因子受体(EGFR)突变状况不明(非选择性)非小细胞肺癌(NSCLC)的疗效和毒性反应。方法老年晚期非选择性NSCLC患者共46例,多西他赛用量60 mg/m2,第1天静脉滴注,卡铂AUC=4,第2天静脉滴注。21~28 d为1个周期,每例患者至少接受2个周期治疗。结果 46例患者均可评价疗效,完全缓解(CR)1例,部分缓解(PR)21例,稳定(SD)19例,进展(PD)5例,总有效率为47.87%(22/46),其中位疾病进展时间为(TTP)5.61个月,中位生存时间(MST)13.21个月(3~20个月),1年生存率为49.21%。主要毒副反应为白细胞下降、骨关节痛、指端麻木、脱发等,积极治疗能控制。结论多西他赛联合卡铂一线治疗老年晚期非选择性NSCLC安全、有效。更多还原

【Abstract】 Objective To observe the efficacy and toxicity of first-line docetaxel and carboplatin treatment for elderly patients with epidermal growth factor receptor(EGFR) or unmutated(non-selective) non-small-cell lung cancer(NSCLC).Methods The study included 46 elderly patients with advanced non-selective NSCLC.The dosage of docetaxel was 60 mg/m2,on day 1,carboplatin AUC=4,on day 2,21-28 d as a therapueutic cyle.Each patient received at least 2-cycle therapy.Results Forty-six patients were evaluable for efficacy.Complete remission(CR) was seen in 1 case,partial remission(PR) in 21 cases,stable(SD) in 19 cases and progress(PD) in 5 cases were reported.The overall efficacy rate was 47.87%(22/46),in which median time to progression(TTP) was 5.61 months,median survival time(MST) was 13.21 months(3 to 20 months),and 1 year survival rate was 49.21%.The main side effects were leukopenia,bone and joint pain,finger numbness,hair loss,and they can be controlled with active treatment.Conclusion First-line docetaxel and carboplatin treatment of advanced non-selective NSCLC is safe and effective.更多还原